Survival and prognostic factors in patients with oral squamous cell carcinoma.
Journal
Medicina oral, patologia oral y cirugia bucal
ISSN: 1698-6946
Titre abrégé: Med Oral Patol Oral Cir Bucal
Pays: Spain
ID NLM: 101231694
Informations de publication
Date de publication:
01 May 2021
01 May 2021
Historique:
received:
15
08
2020
accepted:
24
09
2020
pubmed:
11
10
2020
medline:
5
5
2021
entrez:
10
10
2020
Statut:
epublish
Résumé
This study aimed to evaluate sociodemographic and clinical factors influencing overall survival (OS) in patients with oral squamous cell carcinoma (OSCC). Medical charts of 547 patients with OSCC from a public hospital in northeastern Brazil seen between 1999 and 2013 were evaluated. Survival analysis was performed using the Kaplan-Meier method. The influence of age, sex, ethnicity, clinical stage, anatomical location, type of treatment, and comorbidities on the patients' prognosis was evaluated. Cox proportional hazards regression model was used to identify independent prognostic factors. The 5-year OS was 39%. Multivariate analysis showed that age < 40 years (HR = 2.20; 95%CI: 1.02-4.72) and a single treatment modality (HR = 1.91; 95%CI: 1.37-2.67) were associated with a poor prognosis, while early clinical stage resulted in better outcomes (HR = 0.38; 95%CI: 0.25-0.58). OSCC patients in advanced clinical stages, diagnosed at a younger age, and submitted to a single therapeutic modality have a poorer prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to evaluate sociodemographic and clinical factors influencing overall survival (OS) in patients with oral squamous cell carcinoma (OSCC).
MATERIAL AND METHODS
METHODS
Medical charts of 547 patients with OSCC from a public hospital in northeastern Brazil seen between 1999 and 2013 were evaluated. Survival analysis was performed using the Kaplan-Meier method. The influence of age, sex, ethnicity, clinical stage, anatomical location, type of treatment, and comorbidities on the patients' prognosis was evaluated. Cox proportional hazards regression model was used to identify independent prognostic factors.
RESULTS
RESULTS
The 5-year OS was 39%. Multivariate analysis showed that age < 40 years (HR = 2.20; 95%CI: 1.02-4.72) and a single treatment modality (HR = 1.91; 95%CI: 1.37-2.67) were associated with a poor prognosis, while early clinical stage resulted in better outcomes (HR = 0.38; 95%CI: 0.25-0.58).
CONCLUSIONS
CONCLUSIONS
OSCC patients in advanced clinical stages, diagnosed at a younger age, and submitted to a single therapeutic modality have a poorer prognosis.
Identifiants
pubmed: 33037796
pii: 24242
doi: 10.4317/medoral.24242
pmc: PMC8141315
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e387-e392Références
Cien Saude Colet. 2017 May;22(5):1579-1587
pubmed: 28538928
Int J Dent. 2017;2017:5815493
pubmed: 28638410
J Cancer Res Clin Oncol. 2016 Feb;142(2):521-8
pubmed: 26507889
Anticancer Res. 2019 May;39(5):2527-2533
pubmed: 31092449
Oral Oncol. 2020 Mar;102:104561
pubmed: 31918175
Med Oral Patol Oral Cir Bucal. 2016 May 01;21(3):e285-98
pubmed: 26946200
Br J Oral Maxillofac Surg. 2017 Nov;55(9):911-916
pubmed: 28918183
Med Oral Patol Oral Cir Bucal. 2017 Nov 1;22(6):e679-e685
pubmed: 29053649
Clin Otolaryngol. 2010 Aug;35(4):307-12
pubmed: 20738340
Med Oral Patol Oral Cir Bucal. 2020 May 1;25(3):e416-e424
pubmed: 32134900
Cad Saude Publica. 2019 Nov 28;35(12):e00014319
pubmed: 31800779
Indian J Otolaryngol Head Neck Surg. 2011 Apr;63(2):145-50
pubmed: 22468251
Braz J Otorhinolaryngol. 2020 Jun 24;:
pubmed: 32682819
Einstein (Sao Paulo). 2018 Jun 07;16(2):eAO4248
pubmed: 29898090
Int J Mol Sci. 2018 Aug 16;19(8):
pubmed: 30115834
J Stomatol Oral Maxillofac Surg. 2017 Apr;118(2):103-108
pubmed: 28345518
Head Neck Pathol. 2010 Mar;4(1):53-61
pubmed: 20237990
Cancer Invest. 2019;37(7):275-287
pubmed: 31307249
Adv Ther. 2018 Feb;35(2):153-160
pubmed: 29396681
Exp Oncol. 2020 Mar;42(1):51-59
pubmed: 32231193
Rev Saude Publica. 2013 Jun;47(3):470-8
pubmed: 24346559
Anticancer Res. 2017 Feb;37(2):835-839
pubmed: 28179339
Int J Cancer. 2020 Aug 15;147(4):1040-1049
pubmed: 31953840
Oral Oncol. 2013 Oct;49(10):987-90
pubmed: 23927849
Cancers Head Neck. 2018 Oct 26;3:9
pubmed: 31093362
Ann R Coll Surg Engl. 2020 Mar;102(3):232-235
pubmed: 31841025
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Histopathology. 2011 Jun;58(7):1127-35
pubmed: 21707713
PLoS One. 2013;8(1):e53415
pubmed: 23349710
Curr Oncol Rep. 2017 Aug 10;19(10):65
pubmed: 28799122